Willow Biosciences Inc (D0X) Stock Price & Analysis

2 Followers

D0X Stock Chart & Stats

€0.05€0.01(12.77%)

At close: Nov 10 5:30 PM GMT+1

Day’s Range: EUR 0.05 - EUR 0.05
52-Week Range: EUR 0.04 - EUR 0.12
Previous Close: EUR 0.05
Volume: N/A
Average Volume (3M): 10
Market Cap: EUR 28.83M
Enterprise Value: EUR 59.48M
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: 13.23
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth

A nearly 300% revenue increase signifies accelerating product adoption and expanding customer traction for Willow's fermentation-derived ingredients. This durable top-line momentum supports scale effects, improves leverage on fixed costs, and strengthens the case for continued commercial expansion over the next several months.

Defensible Precision Fermentation Model

Willow's core capability in microbial strain engineering, fermentation and downstream processing is a structural competitive advantage. Precision fermentation addresses sustainability and purity trends in consumer goods, enabling long-term demand, potential premium pricing, and partnership opportunities with CPG and industrial customers.

Improving Free Cash Flow

A substantial reduction in free cash outflow reflects better cost control and operational progress. This durable improvement lengthens runway, reduces near-term financing pressure, and provides management more flexibility to prioritize commercialization and margin expansion over the coming months if the trend continues.

Bears Say

Negative Shareholders' Equity

Negative equity indicates solvency strain and weak balance sheet resilience. This structural weakness limits borrowing capacity, raises creditor and investor concerns, and increases the likelihood of dilutive financing or onerous terms—factors that materially affect strategic flexibility for months ahead.

Ongoing Negative Operating Cash Flow

Persistent negative operating cash flow shows the business is not yet self-sustaining and remains reliant on external capital. Continued cash burn constrains investment in scale-up and commercialization, heightens refinancing risk, and can force short-term tradeoffs that impair long-term execution.

Sustained Net Losses

Despite revenue growth and gross margin improvement, net losses and negative EBIT margins persist, driven by operating expenses. This structural profitability gap must be closed to achieve durable cash generation; until then, profitability remains a multi-quarter risk to financial stability and scaling plans.

Willow Biosciences Inc News

Atlas Energy Secures C$15 Million Alberta Royalty Deal and Exits TSXV Sandbox

The latest announcement is out from Willow Biosciences Inc ( ($TSE:ATLE) ). Atlas Energy Corp has completed a C$15.0 million acquisition of a gross overriding royalty on Caledonian Midstream Corp’s

1M agoD0X ATLE

Atlas Energy Posts Solid Q2 Cash Position as It Advances International Oil and Gas Streaming Strategy

Willow Biosciences Inc ( ($TSE:ATLE) ) has issued an announcement. Atlas Energy Corp., an international upstream royalty and streaming specialist in oil and gas, is building a diversified portfolio of

3M agoD0X ATLE

Atlas Energy Shareholders Back Board, Incentive Plans and Share Consolidation Flexibility

Willow Biosciences Inc ( ($TSE:ATLE) ) has shared an announcement. Atlas Energy Corp. reported the results of its annual general and special meeting, where approximately 80.70% of outstanding shares were

3M agoD0X ATLE

Atlas Energy Highlights Strong Cash Position and Growing Deal Pipeline for 2025

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an announcement. Atlas Energy Corp., an international upstream royalty and streaming company, focuses on building a diversified portfolio of oil and gas

7M agoD0X ATLE

Atlas Energy Corp. Expands Deal Pipeline Amid Favorable Market Conditions

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an update. Atlas Energy Corp. has released its unaudited consolidated interim financial statements for the third quarter of 2025, highlighting a favorable

12M agoD0X ATLE

Atlas Energy Reports Strong Q2 2025 Results and Strategic Recapitalization

Willow Biosciences Inc ( ($TSE:ATLE) ) has shared an announcement. Atlas Energy Corp. has announced its second-quarter financial results for 2025, highlighting a $30 million recapitalization that underscores strong investor

1y agoD0X ATLE

Atlas Energy Corp. Appoints Andy Duncan to Bolster Leadership Team

Willow Biosciences Inc ( ($TSE:ATLE) ) just unveiled an announcement. Atlas Energy Corp. has appointed Andy Duncan as a Senior Executive, bringing over 34 years of experience in the oil

1y agoD0X ATLE

D0X FAQ

What was Willow Biosciences Inc’s price range in the past 12 months?

Willow Biosciences Inc lowest stock price was €0.04 and its highest was €0.12 in the past 12 months.

What is Willow Biosciences Inc’s market cap?

Willow Biosciences Inc’s market cap is €28.83M.

When is Willow Biosciences Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Willow Biosciences Inc’s earnings last quarter?

Willow Biosciences Inc released its earnings results on Aug 13, 2026. The company reported -€0.001 earnings per share for the quarter.

Is Willow Biosciences Inc overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Willow Biosciences Inc pay dividends?

Willow Biosciences Inc does not currently pay dividends.

What is Willow Biosciences Inc’s EPS estimate?

Willow Biosciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Willow Biosciences Inc have?

Willow Biosciences Inc has 466,229,340 shares outstanding.

What happened to Willow Biosciences Inc’s price movement after its last earnings report?

Willow Biosciences Inc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Willow Biosciences Inc?

Currently, no hedge funds are holding shares in DE:D0X

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description